Art. 8 Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 20…

In forcesince 31 Mar 2004cited 8×
1.

Upon receipt of a written request from the Committee for Medicinal Products for Human Use, a Member State shall forward the information showing that the manufacturer of a medicinal product or the importer from a third country is able to manufacture the medicinal product concerned and/or carry out the necessary control tests in accordance with the particulars and documents supplied pursuant to Article 6.

2.

Where it considers it necessary in order to complete its examination of an application, the said Committee may require the applicant to undergo a specific inspection of the manufacturing site of the medicinal product concerned. Such inspections may be made unannounced.

The inspection shall be carried out within the time-limit laid down in the first subparagraph of Article 6(3) by inspectors from the Member State holding the appropriate qualifications; they may be accompanied by a rapporteur or an expert appointed by the Committee.

  • Opinion of Advocate General Sharpston delivered on 31 January 2013. Novartis Pharma GmbH v Apozyt GmbH.Decision

    Articles 4 to 10 set out the procedure relating to applications for the authorisation of a medicinal product. Applications are to be submitted to the European Medicines Agency established under the Regulation, [See Articles 1 and 4(1).] …

    31 Jan 2013 · 62011CC0535

  • Opinion of Advocate General Saugmandsgaard Øe delivered on 25 July 2018. Novartis Farma SpA v Agenzia Italiana del Farmaco (AIFA) and OthersDecision

    The exclusive power that Regulation No 726/2004 confers on the EMA in fact relates only to the evaluations carried out so that the Commission can issue the MA for a medicinal product. [See, in particular, Articles 5 to 9 of Regulation No …

    25 Jul 2018 · 62017CC0029

  • Order of the President of the Court of First Instance of 24 April 2009. Nycomed Danmark ApS v Agence européenne des médicaments (EMEA).Decision

    24 Apr 2009 · 62009TO0052

  • Regulation (EU) 2024/568Law

    1. Inspections au titre de l’article 8, paragraphe 2, de l’article 19 et de l’article 57, paragraphe 1, point i), du règlement (CE) no 726/2004 et de l’article 126, paragraphe 2, du règlement (UE) 2019/6 1.1. Inspections …

  • Judgment of the Court (First Chamber) of 21 November 2018. Novartis Farma SpA v Agenzia Italiana del Farmaco (AIFA) and Others.Decision

    Article 4 of the regulation lays down that applications for MA are to be submitted to the European Medicines Agency (EMA). The requirements for the submission and examination of those applications are set out in Articles 5 to 15 of the …

    21 Nov 2018 · 62017CJ0029

  • Judgment of the General Court (Fifth Chamber), 4 July 2013. Laboratoires CTRS v European Commission.Decision

    … τα στοιχεία και τα έγγραφα που προβλέπονται, ιδίως, στο άρθρο 8, παράγραφος 3, στο άρθρο 10α και στο παράρτημα I της οδηγίας 2001/83.

    4 Jul 2013 · 62012TJ0301

  • Opinion of Advocate General Saugmandsgaard Øe delivered on 21 September 2017. F. Hoffmann-La Roche Ltd and Others v Autorità Garante della CDecision

    … 726/2004 face trimitere la informațiile prevăzute în special la articolul 8 alineatul (3) din această directivă. Mai ales litera (j) din această reglementare menționează RCP. Potrivit articolului 11 din directiva menționată, …

    21 Sep 2017 · 62016CC0179

  • Judgment of the General Court (Tenth Chamber, Extended Composition) of 13 November 2024. Orion Oyj v European Commission.Decision

    … in Article 10(2)(a), as ‘a medicinal product authorised under Article 6, in accordance with the provisions of Article 8 [of the same regulation]’. That abridged procedure exempts the party applying for marketing authorisation for the …

    13 Nov 2024 · 62020TJ0223